Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
about
High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerClass III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancerβIII-Tubulin: biomarker of taxane resistance or drug target?Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineQuantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trialTubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.Increased expression of class III beta-tubulin in castration-resistant human prostate cancerPrognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.[Biomarker docetaxel-based chemotherapy].Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway.β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer.Prognostic value of vascular endothelial growth factor receptor 1 and class III β-tubulin in survival for non-metastatic rectal cancerGenetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance
P2860
Q27851983-31559B5B-93D6-454F-8873-FD0CF9BBE2AEQ28236320-4861C554-D34D-4B22-87A6-5038C9C1CB6FQ28284878-760305AD-3BC3-4F22-AAB2-B6A32B6E32C7Q33817285-D37973E9-2019-4979-981E-1152362690DEQ33914197-83F04562-168A-4548-A7FE-EB70CA42141EQ34428153-292CE94B-76C3-4503-A051-7E8EB4EB3674Q35776779-F9B37E9E-036D-48CB-94B6-94CFAABABC29Q35929796-1867E878-1321-4A71-BA6B-9BC2E2E5EDE0Q36557893-72577C5C-B135-41E3-9D5B-99AF353AE8B1Q36589778-0BB6EF63-7369-44D7-920C-40AEAC06458EQ36718459-7F9F35F8-EE02-4528-8A00-FD55D3ECDEAFQ37347500-267FE28F-317E-435D-91FA-951CCF739B94Q37570220-5C93E2D0-B51E-4578-8B35-A9EBC0889E28Q38719315-A6E71E82-B62F-4E1B-BA57-D912FDD725C2Q38810389-7932962F-6B6B-43E5-8226-B7FE29837652Q38988566-AA7185B4-686E-4CE8-AF24-DAF94B336187Q39636515-0F730875-65CB-478A-AACF-CF6C9F3F9C6EQ39683668-68D8446B-0D05-4F54-B8D7-07341DA6AB9FQ39811005-BBB2DAFF-3E70-4AE2-8700-C92E0E2E34AEQ41143898-341949D3-BAE5-4293-83CE-968F5E4814DFQ42486311-6481B417-33DB-4039-80D5-BDDDC96B18E7Q46262484-B34DB1D9-7C8E-4954-8982-DCCDD3253B26Q50944315-64F1247B-F7BF-447C-86F8-7B9904B19302Q53681641-D846A152-662D-4560-BC33-59A0DF0ADF01Q53837284-59D4DBFB-F7CE-4C5A-A1E6-F2D1BA097984Q58566654-0E43840D-4822-4C4C-A4F6-94B4C19A4D29Q58766772-63430B15-45EF-46E6-A409-A0BD2C9DE94B
P2860
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@ast
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@en
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@nl
type
label
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@ast
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@en
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@nl
prefLabel
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@ast
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@en
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@nl
P2093
P50
P1476
Class III beta-tubulin isotype ...... agent doxorubicin or docetaxel
@en
P2093
Carlos M Galmarini
Chantal Bernard-Marty
David Gancberg
Denis Larsimont
Isabelle Treilleux
Marianne Paesmans
Marie-Christine Bissery
Martine J Piccart
Virginie Durbecq
P304
P356
10.1158/1078-0432.CCR-07-4741
P407
P577
2008-07-01T00:00:00Z